Cargando…
Successful perioperative management of a patient with erythropoietin-producing uterine myoma
BACKGROUND: Erythropoietin-producing uterine myoma can cause various complications such as arterial or venous thrombosis and bleeding. Therefore, caution is required in the anesthetic management of affected patients. CASE PRESENTATION: A 57-year-old female was suspected to have an erythropoietin-pro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967353/ https://www.ncbi.nlm.nih.gov/pubmed/32025892 http://dx.doi.org/10.1186/s40981-018-0185-y |
_version_ | 1783488933907136512 |
---|---|
author | Kobayashi, Masato Akatsu, Masahiko Fujita, Yoshihisa Nishikawa, Koichi |
author_facet | Kobayashi, Masato Akatsu, Masahiko Fujita, Yoshihisa Nishikawa, Koichi |
author_sort | Kobayashi, Masato |
collection | PubMed |
description | BACKGROUND: Erythropoietin-producing uterine myoma can cause various complications such as arterial or venous thrombosis and bleeding. Therefore, caution is required in the anesthetic management of affected patients. CASE PRESENTATION: A 57-year-old female was suspected to have an erythropoietin-producing uterine myoma and was scheduled to undergo an abdominal total hysterectomy and bilateral salpingo-oophorectomy. Preoperative levels of hemoglobin and erythropoietin were 21.9 g/dl (normal 11.5–15 g/dl) and 23.2 IU/ml (normal 4.2–23.7 IU/ml), respectively. Preoperative phlebotomy and isovolemic hemodilution were performed to prevent arterial and venous thrombosis, following previous evidence that a hemoglobin level < 16 g/dl reduces the occurrence of polycythemia vera-related complications. Fondaparinux 2.5 mg was subcutaneously injected once daily after the operation, resulting in a good perioperative course without major complications. CONCLUSION: Herein, we have described a successful perioperative management of a patient with erythropoietin-producing uterine myoma. Our findings in this case suggest that this combination of antithrombotic therapies can facilitate anesthetic management of patients with this disease. |
format | Online Article Text |
id | pubmed-6967353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-69673532020-02-04 Successful perioperative management of a patient with erythropoietin-producing uterine myoma Kobayashi, Masato Akatsu, Masahiko Fujita, Yoshihisa Nishikawa, Koichi JA Clin Rep Case Report BACKGROUND: Erythropoietin-producing uterine myoma can cause various complications such as arterial or venous thrombosis and bleeding. Therefore, caution is required in the anesthetic management of affected patients. CASE PRESENTATION: A 57-year-old female was suspected to have an erythropoietin-producing uterine myoma and was scheduled to undergo an abdominal total hysterectomy and bilateral salpingo-oophorectomy. Preoperative levels of hemoglobin and erythropoietin were 21.9 g/dl (normal 11.5–15 g/dl) and 23.2 IU/ml (normal 4.2–23.7 IU/ml), respectively. Preoperative phlebotomy and isovolemic hemodilution were performed to prevent arterial and venous thrombosis, following previous evidence that a hemoglobin level < 16 g/dl reduces the occurrence of polycythemia vera-related complications. Fondaparinux 2.5 mg was subcutaneously injected once daily after the operation, resulting in a good perioperative course without major complications. CONCLUSION: Herein, we have described a successful perioperative management of a patient with erythropoietin-producing uterine myoma. Our findings in this case suggest that this combination of antithrombotic therapies can facilitate anesthetic management of patients with this disease. Springer Berlin Heidelberg 2018-06-18 /pmc/articles/PMC6967353/ /pubmed/32025892 http://dx.doi.org/10.1186/s40981-018-0185-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Case Report Kobayashi, Masato Akatsu, Masahiko Fujita, Yoshihisa Nishikawa, Koichi Successful perioperative management of a patient with erythropoietin-producing uterine myoma |
title | Successful perioperative management of a patient with erythropoietin-producing uterine myoma |
title_full | Successful perioperative management of a patient with erythropoietin-producing uterine myoma |
title_fullStr | Successful perioperative management of a patient with erythropoietin-producing uterine myoma |
title_full_unstemmed | Successful perioperative management of a patient with erythropoietin-producing uterine myoma |
title_short | Successful perioperative management of a patient with erythropoietin-producing uterine myoma |
title_sort | successful perioperative management of a patient with erythropoietin-producing uterine myoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967353/ https://www.ncbi.nlm.nih.gov/pubmed/32025892 http://dx.doi.org/10.1186/s40981-018-0185-y |
work_keys_str_mv | AT kobayashimasato successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma AT akatsumasahiko successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma AT fujitayoshihisa successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma AT nishikawakoichi successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma |